Characteristics of the randomised patients at start of the run in period
| Fluticasone propionate + salmeterol (n = 139) | Fluticasone propionate double dose (n = 135) | |
|---|---|---|
| Sex (F/M) | 73/66 | 68/67 |
| Age (years) | 46 (15) | 47 (14) |
| FEV1(l) | 2.33 (0.74) | 2.34 (0.75) |
| FEV1 (% pred) | 71 (16) | 73 (16) |
| FVC (l) | 3.69 (1.08) | 3.70 (1.25) |
| FVC (% pred) | 94 (17) | 96 (18) |
| PEF (l/min) | 348 (110) | 358 (129) |
| PEF (% pred) | 75 (21) | 75 (20) |
| Reversibility (% pred FEV1) | 15 (5) | 15 (6) |
Values are mean (SD).
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; PEF = peak expiratory flow; reversibility = increase in % predicted FEV1 after 400 μg salbutamol by metered dose inhaler or 800 μg by dry powder inhaler; % pred = percentage of the predicted value.